PAREXEL International Corporation (PRXL) Given Average Recommendation of “Hold” by Brokerages

Shares of PAREXEL International Corporation (NASDAQ:PRXL) have earned an average rating of “Hold” from the sixteen research firms that are covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and four have assigned a buy rating to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $75.92.

PRXL has been the topic of a number of recent analyst reports. BidaskClub downgraded shares of PAREXEL International Corporation from a “strong-buy” rating to a “buy” rating in a report on Friday, July 28th. Zacks Investment Research raised shares of PAREXEL International Corporation from a “hold” rating to a “buy” rating and set a $98.00 price target on the stock in a report on Tuesday, August 8th. Jefferies Group LLC reissued a “hold” rating and issued a $88.10 price target on shares of PAREXEL International Corporation in a report on Wednesday, June 21st. Raymond James Financial, Inc. raised shares of PAREXEL International Corporation from an “underperform” rating to a “mkt perform” rating in a report on Tuesday, June 20th. Finally, Barclays PLC downgraded shares of PAREXEL International Corporation from an “overweighr” rating to an “equal weight” rating and set a $87.00 price target on the stock. in a report on Tuesday, June 20th.

TRADEMARK VIOLATION WARNING: This piece of content was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this piece of content on another site, it was stolen and reposted in violation of US and international copyright law. The original version of this piece of content can be viewed at https://ledgergazette.com/2017/10/08/parexel-international-corporation-prxl-given-average-recommendation-of-hold-by-brokerages.html.

A number of institutional investors and hedge funds have recently made changes to their positions in PRXL. BlackRock Inc. raised its stake in PAREXEL International Corporation by 22,876.6% in the first quarter. BlackRock Inc. now owns 5,513,456 shares of the medical research company’s stock valued at $347,955,000 after purchasing an additional 5,489,460 shares in the last quarter. Credit Suisse AG raised its stake in PAREXEL International Corporation by 1,897.2% in the first quarter. Credit Suisse AG now owns 2,093,297 shares of the medical research company’s stock valued at $132,108,000 after purchasing an additional 1,988,488 shares in the last quarter. Alpine Associates Management Inc. purchased a new stake in PAREXEL International Corporation in the second quarter valued at approximately $113,716,000. CNH Partners LLC purchased a new stake in PAREXEL International Corporation in the second quarter valued at approximately $109,948,000. Finally, Nomura Holdings Inc. raised its stake in PAREXEL International Corporation by 189.6% in the first quarter. Nomura Holdings Inc. now owns 1,381,087 shares of the medical research company’s stock valued at $87,088,000 after purchasing an additional 904,236 shares in the last quarter. 87.45% of the stock is currently owned by institutional investors and hedge funds.

Shares of PAREXEL International Corporation (NASDAQ:PRXL) traded down 0.02% during trading on Friday, hitting $88.08. 7,021,106 shares of the stock traded hands. The stock has a 50-day moving average of $87.85 and a 200 day moving average of $79.27. PAREXEL International Corporation has a 1-year low of $51.16 and a 1-year high of $88.10. The company has a market cap of $4.50 billion, a P/E ratio of 42.76 and a beta of 0.77.

PAREXEL International Corporation (NASDAQ:PRXL) last announced its quarterly earnings results on Monday, August 28th. The medical research company reported $1.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.94 by $0.08. PAREXEL International Corporation had a net margin of 4.49% and a return on equity of 28.98%. The firm had revenue of $557.20 million for the quarter, compared to the consensus estimate of $5

PRXL has been the topic of a number of recent analyst reports. BidaskClub downgraded shares of PAREXEL International Corporation from a “strong-buy” rating to a “buy” rating in a report on Friday, July 28th. Zacks Investment Research raised shares of PAREXEL International Corporation from a “hold” rating to a “buy” rating and set a $98.00 price target on the stock in a report on Tuesday, August 8th. Jefferies Group LLC reissued a “hold” rating and issued a $88.10 price target on shares of PAREXEL International Corporation in a report on Wednesday, June 21st. Raymond James Financial, Inc. raised shares of PAREXEL International Corporation from an “underperform” rating to a “mkt perform” rating in a report on Tuesday, June 20th. Finally, Barclays PLC downgraded shares of PAREXEL International Corporation from an “overweighr” rating to an “equal weight” rating and set a $87.00 price target on the stock. in a report on Tuesday, June 20th.

TRADEMARK VIOLATION WARNING: This piece of content was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this piece of content on another site, it was stolen and reposted in violation of US and international copyright law. The original version of this piece of content can be viewed at https://ledgergazette.com/2017/10/08/parexel-international-corporation-prxl-given-average-recommendation-of-hold-by-brokerages.html.

A number of institutional investors and hedge funds have recently made changes to their positions in PRXL. BlackRock Inc. raised its stake in PAREXEL International Corporation by 22,876.6% in the first quarter. BlackRock Inc. now owns 5,513,456 shares of the medical research company’s stock valued at $347,955,000 after purchasing an additional 5,489,460 shares in the last quarter. Credit Suisse AG raised its stake in PAREXEL International Corporation by 1,897.2% in the first quarter. Credit Suisse AG now owns 2,093,297 shares of the medical research company’s stock valued at $132,108,000 after purchasing an additional 1,988,488 shares in the last quarter. Alpine Associates Management Inc. purchased a new stake in PAREXEL International Corporation in the second quarter valued at approximately $113,716,000. CNH Partners LLC purchased a new stake in PAREXEL International Corporation in the second quarter valued at approximately $109,948,000. Finally, Nomura Holdings Inc. raised its stake in PAREXEL International Corporation by 189.6% in the first quarter. Nomura Holdings Inc. now owns 1,381,087 shares of the medical research company’s stock valued at $87,088,000 after purchasing an additional 904,236 shares in the last quarter. 87.45% of the stock is currently owned by institutional investors and hedge funds.

Shares of PAREXEL International Corporation (NASDAQ:PRXL) traded down 0.02% during trading on Friday, hitting $88.08. 7,021,106 shares of the stock traded hands. The stock has a 50-day moving average of $87.85 and a 200 day moving average of $79.27. PAREXEL International Corporation has a 1-year low of $51.16 and a 1-year high of $88.10. The company has a market cap of $4.50 billion, a P/E ratio of 42.76 and a beta of 0.77.

PAREXEL International Corporation (NASDAQ:PRXL) last announced its quarterly earnings results on Monday, August 28th. The medical research company reported $1.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.94 by $0.08. PAREXEL International Corporation had a net margin of 4.49% and a return on equity of 28.98%. The firm had revenue of $557.20 million for the quarter, compared to the consensus estimate of $537.59 million. During the same period in the prior year, the firm posted $0.94 earnings per share. On average, equities research analysts predict that PAREXEL International Corporation will post $4.06 EPS for the current fiscal year.

PAREXEL International Corporation Company Profile

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.

Analyst Recommendations for PAREXEL International Corporation (NASDAQ:PRXL)

Receive News & Ratings for PAREXEL International Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply